Well here goes....
yes the cholangiocarcinoma market in the USA is small, but it lets US clinicians use/try oncosil off label in other applications
yes Australia is small but TGA approval might be closer to reimbursement in Australia
it’s not just greater London. Those 9 sites handle all of the pancreatic cancer in England. And that attracts the private patients from the UK and also wealthy Arab states.
agree, though, it needs a boost.
Ann: OncoSil Investor Update, page-23
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $45.40M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.2¢ | 1.1¢ | $32.61K | 2.718M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 3184549 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 2495137 | 4 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| OSL (ASX) Chart |